CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	271.71	371.21	1.2	914.96	0.72	289.59
Revenue Growth (YoY)	171.01%	30885.48%	-99.87%	127154.94%	-99.75%	9169.85%
Gross Profit	271.71	371.21	1.2	914.96	0.72	289.59
Selling, General & Admin	71.76	76.16	102.46	99.69	85.75	63.49
Research & Development	498.59	517.58	571.9	441.75	269.41	179.36
Operating Expenses	570.35	593.74	674.36	541.44	355.15	242.85
Operating Income	-298.64	-222.54	-673.16	373.53	-354.44	46.74
Other Expense / Income	-83.79	-71.82	-22.66	-6	-6.38	-20.57
Pretax Income	-214.84	-150.72	-650.5	379.53	-348.06	67.31
Income Tax	2.29	2.89	-0.33	1.87	0.81	0.45
Net Income	-217.14	-153.61	-650.18	377.66	-348.87	66.86
Shares Outstanding (Basic)	82	79	78	76	66	54
Shares Outstanding (Diluted)	82	79	78	80	66	57
Shares Change	3.96%	1.90%	-3.29%	21.90%	15.84%	18.70%
EPS (Basic)	-2.69	-1.94	-8.36	4.97	-5.29	1.23
EPS (Diluted)	-2.69	-1.94	-8.36	4.70	-5.29	1.17
Free Cash Flow	-166.55	-269.85	-532.93	457.27	-256.72	49.99
Free Cash Flow Per Share	-2.04	-3.41	-6.86	6.02	-3.89	0.92
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-109.91%	-59.95%	-56190.40%	40.82%	-49295.55%	16.14%
Profit Margin	-79.91%	-41.38%	-54271.70%	41.28%	-48520.86%	23.09%
Free Cash Flow Margin	-61.30%	-72.69%	-44484.89%	49.98%	-35705.70%	17.26%
Effective Tax Rate	-	-	-	0.49%	-	0.67%
EBITDA	-195.23	-130.89	-626.33	397.48	-338.87	72.03
EBITDA Margin	-71.85%	-35.26%	-52281.14%	43.44%	-47131.02%	24.87%
Depreciation & Amortization	19.62	19.84	24.17	17.95	9.18	4.73
EBIT	-214.84	-150.72	-650.5	379.53	-348.06	67.31
EBIT Margin	-79.07%	-40.60%	-54298.83%	41.48%	-48408.34%	23.24%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).